These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18901844)

  • 1. [Arsenobenzenes, their composition, their toxicity; an update].
    DE MYTTENAERE F
    J Pharm Belg; 1947; 2(9-10):214-8. PubMed ID: 18901844
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interpretation of blood and skin accidents triggered by arsenobenzenes].
    FLANDIN C; BASSET A; MILLOT J
    Ann Dermatol Syphiligr (Paris); 1945; 5():90. PubMed ID: 21065412
    [No Abstract]   [Full Text] [Related]  

  • 3. [Accidents of treatment with arsenobenzenes; arsenical myelopathy].
    FELDMANN
    Praxis; 1948 Apr; 37(16):294. PubMed ID: 18935002
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental study of the case of urticaria after arsenobenzenes].
    TRAPL J; STAVA Z
    Cesk Dermatol; 1949 Nov; 24(9):364-9. PubMed ID: 15393841
    [No Abstract]   [Full Text] [Related]  

  • 5. [Theoretical notes on the treatment of arsenobenzenes].
    HORACEK J
    Cesk Dermatol; 1949 Nov; 24(9):356-64. PubMed ID: 15407068
    [No Abstract]   [Full Text] [Related]  

  • 6. [The problem of simultaneous treatment with sulfonamides and arsenobenzenes].
    STREITMANN B
    Wien Klin Wochenschr; 1946 Feb; 58(3):44-7. PubMed ID: 20284244
    [No Abstract]   [Full Text] [Related]  

  • 7. [Defense of arsenobenzenes].
    GARNIER G
    Ann Dermatol Syphiligr (Paris); 1946; 6(5-6):283. PubMed ID: 20292546
    [No Abstract]   [Full Text] [Related]  

  • 8. [Review of the treatment of syphilis with arsenobenzenes].
    GARNIER G
    Brux Med; 1948 May; 28(22):1097-1106. PubMed ID: 18864182
    [No Abstract]   [Full Text] [Related]  

  • 9. [Accidents of treatment with arsenobenzenes; myelopathy and arsenical encephalopathy].
    FELDMANN H
    Rev Otoneuroophtalmol; 1949; 21(6):360-7. PubMed ID: 15394278
    [No Abstract]   [Full Text] [Related]  

  • 10. [ACUTE MYELITIS IN A SUBJECT TREATED WITH ARSENOBENZENES].
    SPADETTA V; GAGGINO G
    Rass Med Sarda; 1963; 65():687-92. PubMed ID: 14122975
    [No Abstract]   [Full Text] [Related]  

  • 11. The trypanocidal activity of some pyrimidylaminophenylarsonic compounds.
    AINLEY AD; DAVEY DG
    Br J Pharmacol Chemother; 1958 Sep; 13(3):244-9. PubMed ID: 13584724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A/JAX inbred mice in chemotherapeutic investigations of experimental Chagas' disease.
    Gutteridge WE; Cover B; Gaborak M
    Ann Trop Med Parasitol; 1978 Aug; 72(4):329-38. PubMed ID: 100065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
    Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
    Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    van den Berg MMGA; Kok DE; Posthuma L; Kamps L; Kelfkens CS; Buist N; Geenen M; Haringhuizen A; Heijns JB; van Lieshout RHMA; Los M; Sommeijer DW; Timmer-Bonte JNH; de Kruif ATCM; van Laarhoven HWM; Kampman E; Winkels RM
    Breast Cancer Res Treat; 2019 Jan; 173(2):475-481. PubMed ID: 30353244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of body composition parameters on severe toxicity of nivolumab.
    Hirsch L; Bellesoeur A; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Kirchgesner J; Gervais C; Jouinot A; Chapron J; Giraud F; Wislez M; Alexandre J; Blanchet B; Goldwasser F
    Eur J Cancer; 2020 Jan; 124():170-177. PubMed ID: 31794927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience.
    Desai NB; Stein NF; LaQuaglia MP; Alektiar KM; Kushner BH; Modak S; Magnan HM; Goodman K; Wolden SL
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e67-72. PubMed ID: 23084475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity.
    van Ede AE; Laan RF; Blom HJ; De Abreu RA; van de Putte LB
    Semin Arthritis Rheum; 1998 Apr; 27(5):277-92. PubMed ID: 9572710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cachexia and myopenia - Update on management strategies and the direction of future research for optimizing body composition in cancer - A narrative review.
    Pring ET; Malietzis G; Kennedy RH; Athanasiou T; Jenkins JT
    Cancer Treat Rev; 2018 Nov; 70():245-254. PubMed ID: 30321741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of composition and surface chemistry on the toxicity of quantum dots.
    Sun H; Zhang F; Wei H; Yang B
    J Mater Chem B; 2013 Dec; 1(47):6485-6494. PubMed ID: 32261324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma.
    Kobayashi H; Okuma T; Oka H; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Tsuda Y; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Kawano H; Goto T; Tanaka S
    Int J Clin Oncol; 2019 Apr; 24(4):437-444. PubMed ID: 30465138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.